Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
5.36
-0.14 (-2.55%)
At close: Apr 10, 2026, 4:00 PM EDT
5.37
+0.01 (0.19%)
After-hours: Apr 10, 2026, 7:47 PM EDT
Opus Genetics Employees
As of December 31, 2025, Opus Genetics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 10 or 55.56% compared to the previous year.
Employees
28
Change (1Y)
10
Growth (1Y)
55.56%
Revenue / Employee
$507,000
Profits / Employee
-$1,771,107
Market Cap
381.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 28 | 10 | 55.56% | 27 | 1 |
| Dec 31, 2024 | 18 | 4 | 28.57% | 18 | 0 |
| Dec 31, 2023 | 14 | 5 | 55.56% | 14 | 0 |
| Dec 31, 2022 | 9 | 1 | 12.50% | 9 | 0 |
| Dec 31, 2021 | 8 | 3 | 60.00% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Replimune Group | 479 |
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Nautilus Biotechnology | 130 |
| Neumora Therapeutics | 96 |
| Lineage Cell Therapeutics | 77 |
| Rezolute | 75 |
IRD News
- 1 day ago - Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - GlobeNewsWire
- 5 days ago - Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - GlobeNewsWire
- 18 days ago - Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 2 months ago - Opus Genetics Announces $25 Million Private Placement - GlobeNewsWire